Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1997-11-13
2002-10-08
Caputa, Anthony C. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S830000, C514S870000, C514S886000, C514S906000, C514S929000, C530S324000, C530S307000
Reexamination Certificate
active
06462016
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method for screening for an agonist or antagonist participating in vasodilating action, and compounds obtained by the method. More specifically, the invention relates to a method for screening for an agonist or antagonist using a receptor of maxadilan, and a compound which specifically binds to the receptor, and further, according to circumstances, promotes the cAMP production of a culture cell having a certain cAMP production ability.
2. Description of the Related
Maxadilan is known to exist i n the sialaden of the sand fly
Lutzomyia longipalpis
which is a sucking insect. When applied on the epidermis of animals, maxadilan causes erythema without itch and pain, and is considered to be a strong vasodilator. This biological action is known to be very analogous to the action of calcitonin gene-related peptide (CGRP).
Purification of maxadilan from the salivary glands of the sand fly; the nucleotide sequence encoding its amino acid sequence; and cloning of the gene comprising the nucleotide sequence; and expression of the recombinant maxadilan are announced, for example, in WO 91/00293 and E. A. Lerner et al., J. Bio. Chem. 267, 1062-1066 (1992). Lerner et al. cloned a DNA encoding a fused protein of the recombinant maxadilan with glutathione S-transferase (GST); expressed the fused protein; and cleaved the fused protein with factor Xa; and thereby obtained the recombinant maxadilan as a product in which a peptide fragment (GIL−) consisting of three amino acid residues binds to the N-terminal cysteine of maxadilan (the first cysteine of natural maxadilan; namely corresponding to Cys (1) of SEQ ID NO: 1 of the sequence listing).
Further, the present inventors have already found that a recombinant (see SEQ ID NO: 2) in which a peptide fragment (GSIL−) binds to the N-terminal cysteine of natural maxadilan has an erythema formation activity superior to that of natural maxadilan. In the present specification, maxadilan merely referred to means the recombinant represented by SEQ ID NO: 2.
These recombinant maxadilans are common to CGRP in the point of showing a strong erythema formation activity (hereafter merely referred to as “erythema activity”), but draws attention in the point that they show an erythema activity of almost 500-times that of CGRP per one molecule, and the effect lasts for a longer period of time. Therefore, interest in provision of further variants of maxadilan and evaluation results of these physiological activities is never-ending.
An in vivo test using as erythema formation activity induced by intracutaneously injecting a test polypeptide into white rabbits has been chiefly used in evaluation for the activity. However, a system which is simple and capable of evaluating activities other than erythema formation activity as well as erythema formation activity, is desired. If such an evaluation system is available, it is believed that it will be easy to conduct evaluation on not only variants of maxadilan but various non-peptide compounds.
Thus, the object of the invention lies in providing an in vitro test method, said method being a method for screening for compounds capable of evaluating activities having correlation with the erythema formation activity and other activities. Further, it is also an object of the invention to provide novel compounds selected by such screening method.
SUMMARY OF THE INVENTION
The present inventors have created various variant maxadilans, and have investigated correlation between these structures and actions. Further, we found that maxadilan specifically binds to specific tissue preparations from mammals, and in certain culture cells, the production amount of cyclic adenosine 3′,5′-mono-phosphoric acid (cAMP) is enhanced by maxadilan. Among the above various variant maxadilans, there are those which have the ability to inhibit the binding of maxadilan to the tissue preparation (competitive binding ability), and moreover, enhance cAMP production amount. Thus, it was confirmed that there is a certain correlation between the binding inhibition ability and the cAMP production ability, and the erythema formation ability.
According to the invention, based on such findings, these are provided, for example, as to vasodilating action, according to circumstances, a method for screening for compounds inhibiting such action, and compounds selected by such method.
Thus, the first embodiment of the invention is a method for screening for an agonist or antagonist participating in vasodilating action, said method comprising
(A) a step of preparing a tissue preparation derived from a mammal, to which maxadilan specifically binds,
(B) a step of preparing an analyte
(C) a step of contacting the tissue preparation of the step (A) with the analyte of the step (B),
(D) a step of assaying the binding affinity of the analyte to the tissue preparation, in the step (C),
(E) when the binding affinity in the step (D) is positive, a further step of assaying the influence of the analyte having such action on the cAMP production ability of an animal culture cell to which maxadilan specifically binds and which has a cAMP production ability, and
(F) a step of determining whether the analyte is an agonist or antagonist, based on the results of the step (D) and the step (E)
The second embodiment of the invention is a mammalian preparation having sites (receptors) to which maxadilan specifically binds, the preparation being utilizable for the screening method.
The third embodiment of the invention is a variant maxadilan which specifically binds to a tissue preparation derived from a mammal, having sites to which maxadilan specifically binds, or, according to circumstances, a variant maxadilan which has the above property, and, moreover, promotes the production of cAMP in an animal culture cell which maxadilan specifically binds to and has cAMP production ability.
The thus provided variant maxadilans exhibit binding ability to the receptor of the tissue preparation (ability to competitively inhibit maxadilan), and it is considered that, among them, such a variant maxadilan having, in addition, the cAMP production promotion ability is one acting as an agonist on maxadilan receptors, and such a variant maxadilan exhibiting no cAMP production promotion ability is one acting as an antagonist on maxadilan receptors.
REFERENCES:
patent: 5480864 (1996-01-01), Tajima et al.
patent: 5637309 (1997-06-01), Tajima et al.
patent: 5763271 (1998-06-01), Ribeiro et al.
patent: 91/00293 (1991-01-01), None
patent: 95/04829 (1995-02-01), None
Grevelink et al, J. Pharmacol Exp. Ther, 1995, 216: 234-41.*
Bylund & Yamamura, Methods in Neurotransmitter Receptor Analysis, H.I. Yamanura, Ed, Raven Press, NY, 1990 p. 1-4.*
Entzeroth et al., Lite Sciences 56:PL 19-25.*
Lerner et al (J. Invest. Pernatol, 100, (4) 593, 1993).*
Lerner et al., “Cloning and Functional Expression of the Gene Encoding this Potent Vasodilator Peptide”, The Journal of Biological Chemistry, vol. 267, No. 2, pp. 1062-1066, Jan. 15, 1992.
Ribeiro et al., A Novel Vasodilatory Peptide from the Salivary Glands of the Sand FlyLutzomyia longipalpis, Science, vol. 24, pp. 212-214, 1987.
Smith et al., “Single-Step Purification of Polypeptides Expressed inEscherichia colias Fusions with Glutathione S-transferase”, Gene, 67, pp. 31-40, 1988.
Tortora and Anagnostakos, Principles of anatomy and Physiology, 1984, p. 311.*
Parkinson et al, General Pharmacology, 1994, vol. 25, pp. 1053-1058. Abstract only.*
Chang et al, Neuron, 1993, vol. 11, pp. 1187-1195.Abstract only.*
Carey, Journal of the American society of Nephrology, 1992, vol. 2, pp. 1265-1270. Abstract only.*
Cox et al, Journal of Physiology, 1978, vol. 282, pp. 471-483. Abstract only.*
Phillips et al, Endocrinology, 1990, vol. 126, pp. 1478-1484. Abstract only.*
Nishimura et al, Med J Kinki Univ., 1992, vol. 17, pp. 21-24. Abstract only.*
Burgess et al (J. Cell Bio., 111:2129-2138), 1990.*
Lazar et al (Mol. and Cell. Biol., 8:1247-1252), 1988.*
Tao et al (J. Immu
Lerner Ethan A.
Moro Osamu
Ohnuma Manami
Tajima Masahiro
Wakita Kawori
Canella Karen A.
Caputa Anthony C.
Shiseido Company Ltd.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Method for screening agonist or antagonist of the maxadilan... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for screening agonist or antagonist of the maxadilan..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening agonist or antagonist of the maxadilan... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2952048